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Non-Animal Replacement Methods for Veterinary Vaccine Potency
Testing: State of the Science and Future Directions
Abstract
NICEATM and ICCVAM convened an international workshop to review the state of the science of human
and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and
improved methods that can further reduce, refine, and replace animal use. Six topics were addressed in detail
by speakers and workshop participants and are reported in a series of six reports. This workshop report, the
second in the series, provides recommendations for current and future use of non-animal methods and
strategies for veterinary vaccine potency testing. Workshop participants recommended that future efforts to
replace animal use give priority to vaccines (1) that use large numbers of animals per test and for which many
serials are produced annually, (2) that involve significant animal pain and distress during procedures, (3) for
which the functional protective antigen has been identified, (4) that involve foreign animal/zoonotic
organisms that are dangerous to humans, and (5) that involve pathogens that can be easily spread to wildlife
populations. Vaccines identified as the highest priorities were those for rabies, Leptospira spp., Clostridium spp.,
Erysipelas, foreign animal diseases (FAD), poultry diseases, and fish diseases. Further research on the
identification, purification, and characterization of vaccine protective antigens in veterinary vaccines was also
identified as a priority. Workshop participants recommended priority research, development, and validation
activities to address critical knowledge and data gaps, including opportunities to apply new science and
technology. Recommendations included (1) investigations into the relative impact of various adjuvants on
antigen quantification assays, (2) investigations into extraction methods that could be used for vaccines
containing adjuvants that can interfere with antigen assays, and (3) review of the current status of rabies and
tetanus human vaccine in vitropotency methods for their potential application to the corresponding veterinary
vaccines. Workshop participants recommended enhanced international harmonization and cooperation and
closer collaborations between human and veterinary researchers to expedite progress. Implementation of the
workshop recommendations is expected to advance alternative in vitro methods for veterinary vaccine
potency testing that will benefit animal welfare and replace animal use while ensuring continued protection of
human and animal health.
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Abstract 
NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine 
potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, 
refine, and replace animal use. Six topics were addressed in detail by speakers and workshop participants and are reported in a
series of six reports. This workshop report, the second in the series, provides recommendations for current and future use of non-
animal methods and strategies for veterinary vaccine potency testing. Workshop participants recommended that future efforts to 
replace animal use give priority to vaccines (1) that use large numbers of animals per test and for which many serials are 
produced annually, (2) that involve significant animal pain and distress during procedures, (3) for which the functional protective
antigen has been identified, (4) that involve foreign animal/zoonotic organisms that are dangerous to humans, and (5) that involve
pathogens that can be easily spread to wildlife populations. Vaccines identified as the highest priorities were those for rabies, 
Leptospira spp., Clostridium spp., Erysipelas, foreign animal diseases (FAD), poultry diseases, and fish diseases. Further 
research on the identification, purification, and characterization of vaccine protective antigens in veterinary vaccines was also
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#
 The National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods and the Interagency
Coordinating Committee on the Validation of Alternative Methods 

 Corresponding author e-mail address: stokes@niehs.nih.gov 
This article may be the work product of an employee or group of employees of the National Institute of Environmental Health Sciences
(NIEHS), National Institutes of Health (NIH), or European Commission, however, the statements, opinions or conclusions contained therein do 
not necessarily represent the statements, opinions or conclusions of NIEHS, NIH, the United States government, the European Commission, or 
other organizations. 
1877-282X © 2011 Published by Elsevier Ltd. 
Selection and/or peer-review under responsibility of the National Toxicology Program Interagency Center for the Evaluation of Alternative 
Toxicological Methods (NICEATM).
Open access under CC BY-NC-ND license.
61Jodie Kulpa-Eddy et al. / Procedia in Vaccinology 5 (2011) 60 – 83 61 Jodie Kulpa-Eddy et al. /  Procedia in Vaccinology  5 ( 2011 )  60 – 83 
critical knowledge and data gaps, including opportunities to apply new science and technology. Recommendations included (1) 
investigations into the relative impact of various adjuvants on antigen quantification assays, (2) investigations into extraction
methods that could be used for vaccines containing adjuvants that can interfere with antigen assays, and (3) review of the current
status of rabies and tetanus human vaccine in vitro potency methods for their potential application to the corresponding 
veterinary vaccines. Workshop participants recommended enhanced international harmonization and cooperation and closer 
collaborations between human and veterinary researchers to expedite progress. Implementation of the workshop 
recommendations is expected to advance alternative in vitro methods for veterinary vaccine potency testing that will benefit 
animal welfare and replace animal use while ensuring continued protection of human and animal health. 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the National Toxicology Program 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
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1. Introduction 
Veterinary vaccines contribute to improved human and animal health and welfare by preventing and controlling 
infectious agents that can cause disease and death. However, the testing necessary to ensure vaccine effectiveness 
and safety can involve large numbers of animals and significant pain and distress. In the United States, the 
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National 
Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
promote the scientific validation and regulatory acceptance of test methods that accurately assess the safety of 
chemicals and products while reducing, refining (less pain and distress), and replacing animal use. Accordingly, 
NICEATM and ICCVAM recently identified vaccine potency and safety testing as one of their four highest 
priorities [1].  
ICCVAM is an interagency committee of Federal agencies that is charged by law with evaluating new, revised, 
and alternative test methods with regulatory applicability. ICCVAM members represent 15 U.S. Federal regulatory 
and research agencies that require, use, generate, or disseminate safety testing data. These include the Department of 
Agriculture (USDA), which regulates veterinary vaccines, and the Food and Drug Administration (FDA), which 
regulates human vaccines. ICCVAM is a permanent interagency committee of the National Institute of 
Environmental Health Sciences (NIEHS) under NICEATM. NICEATM administers ICCVAM, provides scientific 
and operational support for ICCVAM-related activities, and conducts international validation studies on promising 
new safety testing methods. NICEATM and ICCVAM serve a critical public health role in translating research 
advances from the bench into standardized safety testing methods that can be used in regulatory practice to prevent 
disease and injury. 
To promote and advance the development and use of scientifically valid alternative methods for human and 
veterinary vaccine testing, NICEATM and ICCVAM organized the International Workshop on Alternative Methods 
to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and 
Future Directions. The workshop was held at the National Institutes of Health in Bethesda, Maryland, on September 
14–16, 2010. It was organized in conjunction with the European Centre for the Validation of Alternative Methods 
(ECVAM), the Japanese Center for the Validation of Alternative Methods (JaCVAM), and Health Canada. 
The workshop addressed the state of the science of human and veterinary vaccine potency and safety testing. 
Participants developed recommendations for future progress in three major areas: (1) in vitro replacement methods 
for potency testing; (2) reduction and refinement methods for potency testing; and (3) reduction, refinement, and 
replacement methods for vaccine safety testing [2]. Reports were prepared for each of the three topics for human 
vaccines and for each of the three topics for veterinary vaccines [3, 4, 5, 6, 7, 8]. This report addresses methods and 
strategies for the replacement of animal use for potency testing of veterinary vaccines.
 20  Pu lis e   lse ier td. election and/or peer-review under responsibility of the National Toxicology 
Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the National Toxicology Program 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM). Open access under CC BY-NC-ND license.
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2. Goals and organization of the workshop 
The goals of the international workshop were to (1) identify and promote the implementation of currently 
available and accepted alternative methods that can reduce, refine, and replace the use of animals in human and 
veterinary vaccine potency and safety testing; (2) review the state of the science of alternative methods and identify 
knowledge and data gaps that need to be addressed; and (3) identify and prioritize research, development, and 
validation efforts needed to address these gaps in order to advance alternative methods that will also ensure 
continued protection of human and animal health. 
The workshop was organized with four plenary sessions and three breakout group sessions. In the breakout 
sessions, workshop participants: 
x Identified criteria to prioritize vaccine potency and safety tests for future alternative test method development and 
identified high priorities using these criteria 
x Reviewed the current state of the science of alternative methods and discussed ways to promote the 
implementation of available methods 
x Identified knowledge and data gaps that need to be addressed 
x Identified and prioritized research, development, and validation efforts needed to address these gaps in order to 
advance alternative methods while ensuring continued protection of human and animal health 
The workshop opened with a plenary session in which expert scientists and regulatory authorities from the United 
States, Europe, Japan, and Canada outlined the importance of vaccines to human and animal health [9, 10] and 
described national and international regulatory testing requirements for human and veterinary vaccines [2, 11, 12, 
13, 14, 15, 16]. Authorities emphasized that, following the regulatory approval of a vaccine, testing is required to 
ensure that each subsequent production lot is pure, safe, and sufficiently potent to generate a protective immune 
response in people or animals [11, 12]. 
The second plenary session addressed methods that have been accepted and methods that are in development that 
do not require the use of animals for assessing the potency of vaccines [17, 18, 19, 20]. This was followed by 
breakout sessions to discuss the state of the science and recommendations for future progress for in vitro potency 
tests for human and veterinary vaccines. This paper provides workshop recommendations to advance the use and 
development of alternative methods that can replace animals for the potency testing of veterinary vaccines. 
Recommendations for human vaccines are available elsewhere in these proceedings [3]. 
The third plenary session addressed (1) potency testing methods that refine procedures to avoid or lessen pain and 
distress by incorporating earlier humane endpoints or by using antibody quantification tests instead of challenge 
tests and (2) methods and approaches that reduce the number of animals required for each test [21, 22, 23, 24, 25, 
26, 27]. Breakout groups then discussed the state of the science and developed recommendations for future progress. 
Workshop recommendations to advance the use and development of alternative methods that can reduce and refine 
animal use for potency testing of human vaccines [5] and veterinary vaccines [6] are available in the respective 
papers in these proceedings. 
The final plenary session addressed methods and approaches for reducing, refining, and replacing animal use to 
assess the safety of serial production lots of human and veterinary vaccines [11, 28, 29, 30]. Breakout groups then 
discussed the state of the science and developed recommendations for advancing alternative methods for vaccine 
safety testing. Workshop recommendations to advance the use and development of alternative methods for safety 
testing of human vaccines [7] and veterinary vaccines [8] are available in these proceedings. 
3. Requirements for veterinary vaccine potency testing
Strict regulations and guidelines are designed to ensure that every veterinary vaccine distributed in or from the 
United States is pure, safe, potent, and effective [31]. An estimated 18,000 serials (batches) of veterinary vaccines 
are released annually in the United States for approximately 2000 different products that protect animals from 
213 different animal diseases [12].Given that many inactivated vaccines still require animals for potency testing, 
significant numbers of animals are necessary.  
Veterinary vaccines contribute to the health and well being of people and animals. In addition to controlling and 
preventing diseases of companion and domestic animals, vaccines help ensure a safe and efficient global food 
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supply. They reduce the transmission of zoonotic and foodborne infections from animals to people. Vaccines also 
reduce the need for low-level antibiotics to control some diseases in food animals. 
Due to the number of animals used annually for the release of veterinary vaccines, global regulatory agencies 
actively encourage the evaluation, development, and implementation of novel approaches that reduce, refine, and 
replace (3Rs) the use of animals in vaccine safety and potency product release testing [12, 14, 22]. 
4. Prioritizing vaccine potency tests for future replacement activities 
Potency testing procedures for many veterinary vaccines still require the use of animals; therefore, the 
development and validation of additional replacement tests could significantly benefit animal health and welfare. 
Workshop participants prioritized the veterinary vaccines that should be targeted for further development and 
validation of in vitro replacement tests. The criteria for prioritization included:
x Vaccines that use large numbers of animals per test and for which many serials are produced annually 
x Vaccines that involve significant animal pain and distress during testing procedures 
x Vaccines for which the functional protective antigen has been identified and characterized 
x Vaccines that involve foreign animal/zoonotic organisms  
x Vaccines that involve pathogens that can be easily spread to wildlife populations 
Based on these criteria, the following vaccines were given highest priority for further development of alternative 
replacement methods:  
x Rabies vaccines 
x Leptospira spp. vaccines 
x Clostridium spp. vaccines 
x Erysipelas vaccines 
x Vaccines for foreign animal diseases (FADs) especially those posing viral biohazards that require enhanced 
security and biosafety measures (e.g., foot and mouth disease [FMD] and bluetongue disease) 
x Poultry vaccines 
x Fish vaccines 
x New vaccines that are currently undergoing prelicensing development and evaluation 
Rabies, Leptospira spp., and Clostridium spp. vaccines were identified as the highest priorities because their 
required potency tests use large numbers of animals and involve significant pain and distress. For example, analysis 
of serials released in the UK between 2007 and 2009 indicated that potency tests involving live challenge testing for 
Leptospira spp. and rabies vaccines accounted for a high proportion (>25%) of animals used in batch potency testing 
[14]. Vaccine challenge tests that require live viruses and bacteria that are hazardous to laboratory workers, 
livestock, companion animals, and wildlife were also considered high priorities (e.g., rabies and FMD vaccines). In 
addition, prioritization of vaccines for which the functional protective antigen has previously been identified would 
greatly facilitate the successful development of antigen quantification methods. Finally, new vaccines were included 
as high priorities in order to encourage the development of replacement alternatives early in the development cycle. 
As shown in Table 1, several of the vaccines identified as high priorities, those that currently use animals in 
vaccination-challenge or toxin-neutralization testing, have alternative serology methods either in development or 
accepted for use by specific regulatory authorities. Therefore, validated refinement methods already exist and 
represent critical first steps toward the ultimate goal of identifying in vitro replacement methods for these high-
priority vaccines.
For many veterinary vaccines, regional differences affect the availability and implementation of in vitro
replacement assays. For example, the USDA published an in vitro ELISA potency test for inactivated swine 
erysipelas vaccine (Erysipelothrix rhusiopathiae), while the European Directorate for the Quality of Medicines & 
HealthCare (EDQM) published a mouse-based serology test in the European Pharmacopoiea (Ph. Eur.) (Table 2).
The EDQM has developed, validated, and approved an in vitro test for inactivated Newcastle disease vaccine that is 
not a standard requirement in the United States (Table 2). Clearly, improved international communication and 
harmonization may expand the number of veterinary vaccines for which replacement methods are available and/or 
accepted for use. However, regional differences in disease status, product composition, number of manufacturers, 
and funding may all affect priorities established in those specific regions. 
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Table 1. Targets for non-animal replacements: examples of veterinary vaccine potency assays using animals 
for immunization (serology), challenge testing, or toxin–antitoxin neutralization testing 
Vaccine Product 
(Disease) 
3Rs Alternative 
Traditional Test Procedure 
for Which the Alternative 
Method is Applicable
Regulatory
References
Scientific
References
Inactivated Bacterins and Toxoids 
Clostridium novyi (Type B); 
Bovine (black disease) 
Immunization (rabbits) and 
serologya, b- In vitro 
immunochemical method or 
neutralization in cell culture 
(specific details not provided in 
the Ph. Eur. monograph) 
Rabbit immunization/Mouse 
toxin neutralization test 
USDA SAM 207 
(2007) [32]; 
9 CFR 113.108; Ph. 
Eur. Monograph 362 
[33]  
EDQM 2007 
[34]; 
Hendriksen et 
al. 1998 [35] 
Clostridium septicum; Bovine 
(malignant edema) 
Immunization (rabbits) and 
Serologyb, c- In vitro 
Immunochemical method or 
neutralization in cell culture 
(specific details not provided in 
the Ph. Eur. monograph) 
Rabbit immunization/mouse 
toxin neutralization test 
Ph. Eur. Monograph 
364 [36] 
EDQM 1997, 
2007;
Hendriksen et 
al. 1998 [35] 
Clostridium perfringens C/D; 
Bovine (enterotoxemia) 
Immunization (rabbits) and 
serologyb, c- In vitro
immunochemical method or 
neutralization in cell culture 
(specific details not provided in 
the Ph. Eur. monograph) 
Rabbit immunization/mouse 
toxin neutralization test 
USDA SAM 201 (Type 
C, 2008) [37]; SAM 
203 (Type D, 2007) 
[38]; 9 CFR 113.111 
and 112; Ph. Eur. 
Monograph 363 [39] 
Rosskopf-
Streicher et al. 
2004 [40]; 
EDQM 2007 
[34]; 
Hendriksen et 
al. 1998 [35] 
Clostridium sordellii; Bovine 
(big head) 
- Rabbit immunization/ mouse 
toxin neutralization test 
USDA SAM 212 
(2007) [41]; 
9 CFR 113.109  
-
Clostridium haemolyticum;
Bovine (red water disease) 
- Immunization followed by 
live spore challenge in guinea 
pigs
USDA SAM 209 
(2008) [42]; 
9 CFR 113.107  
-
Tetanus antitoxin products; 
Equine (Clostridium tetani)
Immunization and serologya,,b
(guinea pigs) – In vitro toxin 
binding inhibition (TOBI), 
indirect ELISAa
Guinea pig 
immunization/Guinea pig 
toxin–antitoxin neutralization 
teste
USDA SAM 206 
(2007) [43]; USDA 
SAM 217 (2009) [44]; 
Ph. Eur. Monograph 
697 [45]; Council of 
Europe 1996 [46] 
Hendriksen et 
al. 1994 [47] 
Leptospira interrogans 
Serovar canicola bacterin 
Canine leptospiral 
(adjuvanted and non-
adjuvanted),
Immunization and serologyb,d
(hamsters) (in vitro method to 
determine antibody levels, no 
further details provided in the 
Ph. Eur.) 
Immunization challenge test 
in hamstersf
USDA SAM 625 
(2009) [48]; 
9 CFR 113.103;  
Ph. Eur. Monograph 
447 [49] 
-
Leptospira interrogans 
Serovar hardjo bacterin 
Bovine Leptospira hardjo
Immunization and serologyb,d
(guinea pigs) – micro-
agglutination test 
Cattle immunization 
challengeg: Immunization 
challenge test in hamsters 
9 CFR 113.105 [50];  
Ph. Eur. Monograph 
1939 [51] 
-
Inactivated Viral Vaccines 
Rabies vaccine (Lyssavirus
rabies)
Immunization (mice) and 
serologyb– In vitro rapid 
fluorescent focus inhibition test 
(RFFIT)
Immunization challenge in 
mice (intracerebral)h
USDA SAM 308 
(2007) [52]; 
9 CFR 113.209; 
Ph. Eur. Monograph 
451 [53] 
Cliquet et al. 
1998 [54]; 
Kramer et al. 
2009 [55], 2010 
[56]; Nagarajan 
et al. 2006 [57] 
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Vaccine Product 
(Disease) 
3Rs Alternative 
Traditional Test Procedure 
for Which the Alternative 
Method is Applicable
Regulatory
References
Scientific
References
European foot and mouth 
disease vaccine; Foot-and-
mouth disease virus; Bovine 
- Viral challenge of vaccinated 
cattle
- Golde et al. 
2005 [58]; 
Rodriquez and 
Grubman 2009 
[59] 
aAccepted by U.S. regulatory authorities. 
bPublished in the European Pharmacopoeia.  
cThe European Pharmacopoeia states that following serology, an immunochemical method or neutralization in cell cultures is considered 
acceptable following product specific validation.
dApplicable after in-house (product-specific) validation.  
eNo longer listed in the European Pharmacopoeia. 
fThe European Pharmacopoeia states endpoint is “signs” of the disease and not lethality.  
gThe European Pharmacopoeia states that cattle are used for prelicensing while serology in guinea pigs is conducted for routine batch release 
testing.
hNot for routine batch release (European Pharmacopoeia). 
5. Veterinary vaccine potency testing: non-animal replacement alternative methods
5.1. State of the science 
Current veterinary vaccines consist of (1) modified live (attenuated) virus and bacteria, (2) inactivated (killed) 
viruses and bacteria, (3) toxoid or bacterin toxoids, (4) peptide and subunit vaccines, and (5) genetically engineered 
products. The general types of potency tests employed by vaccine manufacturers include the following: 
x Titration of live organisms (in vitro but occasionally in vivo)
x In vitro assays such as ELISAs or other quantitative methods 
x Serology methods (in vivo to in vitro)
x Vaccination–challenge in vivo methods using either the host animal (fish, poultry) or laboratory animals (e.g., 
hamsters, mice) [17]  
For a typical U.S. veterinary vaccine manufacturer, 37% of tests use in vitro titration assays, 22% use in vitro
ELISAs, 12% use some other in vitro method, 8% use in vivo serology test, and 21% use in vivo vaccination–
challenge methods [17]. These data exclude poultry and fish vaccine potency testing but do suggest that in vitro
methods are being applied for most potency testing conducted on veterinary vaccines. Animal welfare concerns, 
increased scientific accuracy, and the financial benefits associated with in vitro assays provide significant incentives 
to veterinary vaccine manufacturers for the replacement of animals for potency testing procedures, especially if a 
vaccine product can be released without the potential concern for repeat in vivo testing [17, 60].  
5.1.1. Modified live vaccines 
In vitro potency testing procedures are currently used in the release of many modified live (attenuated) and 
genetically modified vaccines (Table 2) but are not widely used for the potency release of inactivated vaccines. In 
the United States, the USDA’s Center for Veterinary Biologics (CVB) publishes many supplemental assay methods 
(SAMs) that provide detailed, validated protocols for the safe and effective potency testing of specific veterinary 
vaccines. To further facilitate the use of alternative in vitro methods, the CVB and other regulatory authorities 
provide many of the critical reagents and reference standards necessary to conduct these potency assays.  
In vitro potency methods for the quantification of several modified live bacterial vaccines are currently outlined 
in publicly available USDA SAMs. For example, enumeration methods that quantify the colony-forming units 
(CFUs) of specified live organisms are described for Brucella abortus [48], Erysipelothrix rhusiopathiae [61], and 
avirulent Pasteurella haemolytica (new name Mannheimia haemolytica) [62] vaccines. In addition, the CVB has 
published an in vitro potency assay that uses indirect fluorescent antibody staining of inoculated cell culture to 
quantify bacterial titers for Chlamydophila felis (formerly feline Chlamydia psittaci) [63]. As the majority of 
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bacterial vaccines for veterinary use are inactivated, toxoid- or bacterin–toxoid-based, there are relatively few 
modified live bacterial vaccines available for veterinary use. 
For live or genetically engineered viruses, virus titration is performed in cell cultures using endpoints such as 
plaque formation; cytopathology; and, indirectly, virus neutralization by virus-specific serological reagents. For 
example, in vitro titration assays utilizing the enumeration of plaque-forming units (PFUs) are available for feline 
calicivirus [64], feline rhinotracheitis virus [65], and Marek’s disease vaccines [66].
For other live viral vaccines, the virus is quantified by determining its cytopathic effect in primary cell culture. 
These include vaccines for the following: 
x Porcine transmissible gastroenteritis [67] 
x Porcine rotavirus [68] 
x Infectious canine hepatitis [69]  
x Canine adenovirus [70]  
x Canine distemper [64] 
x Infectious bursal disease [71]  
Finally, some modified live viral vaccines, such as those for feline panleukopenia [72] and canine parvovirus 
[73], quantify virus titers using direct or indirect fluorescent antibody staining of virus-inoculated cell cultures. 
Although these assay methods are approved by the USDA, it is often difficult to estimate which procedures are 
routinely used to release vaccine products because product-specific validation is required. However, it is estimated 
that approximately 50% of all U.S. veterinary vaccine serials are now released based on in vitro potency testing 
[26]. Examples of modified live veterinary vaccine potency assays that do not require the use of animals are 
provided in Table 2.
Other live vaccines, such as mink distemper virus vaccines [74], use an alternative in vitro system to quantify 
viral content by counting viral plaques that grow on the chorioallantoic membrane of inoculated chicken embryos. 
For live chicken embryo-adapted Chlamydophilia felis vaccine [75], embryonated chicken eggs are used as the 
indicator host system to determine vaccine titer (Table 2). In addition, a procedure is available for titrating 
Newcastle disease virus (NDV), infectious bronchitis virus (IBV), and combination NDV–IBV vaccines through the 
inoculation of embryonated chicken eggs in order to calculate the 50% egg infective dose (EID50) [76]. The 
majority of modified live vaccines use in vitro methods for potency release, however, some live attenuated vaccines, 
such as ovine ecthyma vaccine for sheep [77], still require a target animal vaccination–challenge potency test. 
5.1.2. Inactivated vaccines 
For many inactivated veterinary vaccines, especially bacterial vaccines, a key hurdle to the successful 
development of in vitro antigen quantification assays is the lack of protective antigen identity and the inclusion of 
complex adjuvants in vaccine formulations [60]. Therefore, many inactivated veterinary vaccines still require in vivo
methods (i.e., serology or vaccination–challenge methods) for determining relative potency.  
However, there are specific examples in which the protective antigen for an inactivated bacterial vaccine has 
been identified and used to develop a specific ELISA quantification assay based on comparison to a reference 
standard of antigen. These include reference standards available from CVB or product-specific standards developed 
by the manufacturer. Examples include Erysipelothrix rhusiopathiae bacterins for 65kD protein [78] and 
Escherichia coli bacterins testing for K99 Pilus [79], K88 Pilus [79], 987P Pilus [79] and P41 Pilus [79]. The 
development of the swine erysipelas potency test also included extensive work to develop humane endpoints [80] 
and an ELISA serology test [40].  
For the potency determination of various Leptospira interrogans serovars, an in vitro ELISA assay is used to 
measure the relative potency of specific bacterins compared to a suitably qualified reference standard, such as the 
one available from the CVB. The Leptospira interrogans serovars tested in this way include pomona [81], canicola 
[48], grippotyphosa [82], and icterohaemorrhagiae [83].  
Published in vitro assays are also available for selected inactivated virus vaccines. For example, the potency of an 
inactivated respiratory cattle vaccine containing several bovine respiratory viruses (bovine diarrhea [BVD], bovine 
respiratory syncytial virus [BRSV], bovine rhinotracheitis [BRV], bovine parainfluenza [PI3]] is determined using 
an ELISA assay relative to a reference standard [84]. Additional in vitro methods have been published for feline 
leukemia virus GP70 antigen quantification [85] and inactivated canine coronavirus vaccines [86].
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An in vitro ELISA antigen quantification assay for inactivated NDV vaccine has been developed and validated 
by the EDQM [18, 87, 88, 89]. The successful transition from an in vivo assay to an in vitro ELISA was aided by the 
fact that there was a strong correlation between antigen content and antibody response. The antigen-specific 
antibodies correlated with protection, and the European NDV vaccines were a homologous group with a single 
serotype and comparable oil-based adjuvants. Even with these distinct advantages, the replacement test took almost 
10 years (1997–2006) to be incorporated in the EU monograph for inactivated Newcastle vaccines [18, 88, 90, 91]. 
Although publication in the EU monograph is encouraging, the in vitro assay is only optional because it is one of 
several approved assays for inactivated Newcastle vaccines currently included in the monograph. Accordingly, it is 
difficult to estimate how widely this or any other replacement assay is used by vaccine manufacturers to release 
vaccine products. 
Table 2 provides specific examples of potency tests for inactivated veterinary vaccines that do not require the use 
of animals. This is not an exhaustive list, and in some cases general methods are available, often without detailed 
methodologies. Adding to the complexity, these references do not clearly indicate what assays are being used to 
release a product. Nor do they indicate that multiple methods may be available and approved for a specific vaccine 
by a specific regulatory agency.
The proceedings of the EDQM International Symposium on Alternatives to Animal Testing included a report 
provided by vaccine manufacturer Intervet International on the development of alternative veterinary vaccine 
potency tests [92]. According to this report, alternative in vitro potency tests for inactivated veterinary vaccines are 
described in only a few individual monographs. For example, of the inactivated mammalian veterinary vaccines 
released from the Intervet Boxmeer facility, 33 separate potency tests are conducted of which three utilize 
vaccination/challenge tests, 28 use serology, and two use in vitro techniques. The EU monographs provide detailed 
descriptions of only 13 of the 33 tests. Both of the in vitro tests used by Intervet are described.  
For inactivated poultry vaccines, Intervet conducts 16 potency tests: three use vaccination–challenge methods, 14 
use serology, and one has a serology or challenge option. Twelve of these potency tests are currently described in 
EU monographs with one in vitro alternative also described (currently not in use by Intervet) [92]. For fish vaccines, 
Intervet uses 11 potency tests, all of them vaccination–challenge tests. Five of the 11 are described in EU 
monographs. As yet, no in vitro alternatives are provided. Although this represents only one vaccine manufacturer’s 
potency release of inactivated veterinary products, for which fewer in vitro methods currently exist, it does provide 
some indication of the potency tests utilized and the need for improved availability of both general and detailed in 
vitro methods.  
5.2. Knowledge gaps and priority research, development, and validation activities 
The development of in vitro potency assays for the highest-priority vaccines that still use animals requires an 
understanding of the knowledge and data gaps that have delayed the introduction of such non-animal assays. 
Understanding the protective antigen was identified as the primary technical issue. However, for many veterinary 
vaccines, especially bacterial vaccine products, the protective antigen is unknown or is a complex combination of 
antigens [17]. Therefore, development of antigen quantification tests is technically difficult because demonstrating a 
dose response between an antigen and protection in the target species may not be possible.  
Future efforts could focus upon cloning the genes for the protective antigens or obtaining the rights to those 
genes that have already been cloned during the development of reference standards. Purification methods could then 
be developed for the protective antigens, these antigens characterized, and appropriate assays developed and 
validated. Purified antigens may be made available to industry as reference standards.  
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Table 2. Examples of veterinary vaccine potency assays that incorporate in vitro non-animal alternative 
methods
Vaccine Product 
(Disease) 
3Rs Alternative References for Alternative Methods
Traditional Test 
Procedure for which the 
Alternative Method is 
Applicable
References
for 
Traditional
Methods 
Modified Live Bacterial Vaccines 
Brucella abortusa
(Cattle brucellosis) 
In vitro titration method 
determining colony forming 
units (tryptose agar) 
USDA SAM 600 (2009)d;
9CFR113.65 [93]
- -
Erysipelothrix rhusiopathiaea
(Swine Erysipelas) 
In vitro titration method 
determining colony forming 
units (5% bovine blood agar) 
USDA SAM 612 (2007) 
[61] 
Vaccination Challenge 
test in swine 
9CFR.113.67 
[61] 
Mannheimia haemolyticaa
(Pasteurella haemolytica)
(Cattle respiratory disease) 
In vitro titration method 
determining colony forming 
units (trypticase Soy Agar) 
USDA SAM 905 (2009); 
9CFR113.68 [62] 
Vaccination Challenge 
test in cattle 
-
Chlamydophila felisa
(Feline respiratory disease) 
Cell culture- in vitro titration 
method utilizing indirect 
fluorescent antibody staining 
(mouse fibroblasts; MEM) 
USDA SAM 319 (2007); 
9CFR113.71 [63] 
- -
Modified Live Viral Vaccines 
Feline Calicivirusa
(Feline respiratory disease) 
Cell culture- in vitro titration 
method utilizing plaque 
forming units (Crandall feline 
kidney cells; MEM) 
USDA SAM 306 (2008); 
9CFR113.314 [64] 
- -
Feline Rhinotracheitis Virusa
Feline respiratory disease) 
Cell culture- in vitro titration 
method utilizing plaque 
forming units (Crandall feline 
kidney cells; MEM) 
USDA SAM 307 (2008); 
9CFR113.315 [65] 
- -
Mareks Disease Virusa
(Poultry neoplastic disease) 
Cell culture- in vitro titration 
method (primary chick 
embryo fibroblasts; M199) 
USDA SAM 406 (2005); 
9CFR113.330 [66] 
Vaccination Challenge 
test in chickens 
Ph. Eur. 
Monograph 
589 [94] 
Porcine Transmissible 
Gastroenteritis: caused by 
Coronavirus TGEVa
(Swine infectious diarrhea) 
Cell culture- in vitro titration 
method utilizing cytopathic 
effect (swine testicular cells; 
MEM)
USDA SAM 114 (2005) 
[67]
Porcine Rotavirusa
(Swine infectious diarrhea) 
Cell culture- in vitro method 
utilizing cytopathic effect or 
indirect fluorescent antibody 
technique (Rhesus monkey 
kidney cells; MEM) 
USDA SAM 121 (2005) 
[68] 
- -
Infectious Canine Hepatitis: 
caused by Canine Adenovirus 
type 1a
(Canine hepatitis) 
Cell culture- in vitro method 
utilizing cytopathic effect 
(primary dog kidney cells; 
MEM)
USDA SAM 304 (2007); 
9CFR113.305 [69] 
- -
Canine Distemper Virusa
(Canine viral disease) 
Cell culture- in vitro method 
utilizing cytopathic effect 
(Vero cells; MEM) 
USDA SAM 323 (2007); 
9CFR113.306 [64] 
- -
Infectious Bursal Disease 
Virus (IBDV)a
(Poultry immuno-suppressive 
disease)
Cell culture- in vitro titration 
method of tissue culture 
adapted IBDV (primary chick 
embryo FB; M199/F10) 
USDA SAM 408 (2007); 
9CFR113.331 [71] 
Immunization Challenge 
test in chickens 
Ph. Eur. 
Monograph 
587 [95]; 
Thornton 
1976 [96] 
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Vaccine Product 
(Disease) 
3Rs Alternative References for Alternative Methods
Traditional Test 
Procedure for which the 
Alternative Method is 
Applicable
References
for 
Traditional
Methods 
Feline Panleukopenia: caused 
by Feline Parvovirusa
(Feline viral disease) 
USDA SAM 305 (2007); 
9CFR113.304 [69] 
- -
Canine Parvovirusa
(Canine viral disease) 
Cell culture- in vitro titration 
method utilizing indirect 
fluorescent antibody straining 
(Crandall feline kidney cells; 
MEM) USDA SAM 316 (2007); 9CFR113.307 [73] 
- -
Mink Distemper Virusa
(Mink viral disease) 
Embryonated chicken eggs - 
titration of viral plaques on 
chorioallantoic membrane 
(CAM)
USDA SAM 303 (2007); 
9CFR113.302 [74] 
Immunization Challenge 
test in minks 
-
Inactivated Bacterial Vaccines or Bacterins 
Erysipelothrix rhusiopathiaea
(inactivated)
(Swine Erysipelas) 
USDA SAM 613 (2009); 
9CFR113.119 [78] 
Immunization Challenge 
test in mice 
USDA SAM 
611 (2008); 
9CFR113.119 
[97] 
Escherichia coli bacterinsa
(Multi-species gastro-
intestinal)
USDA SAM 620 (K99 
Pilus), 621 (K88 Pilus), 
622 (987P Pilus), and 623 
(F41 Pilus) (2010) [79] 
- -
Leptospira interrogans 
Serovar pomona bacterina
(swine, cattle, sheep, goats, 
canine, equine Leptospirosis) 
USDA SAM 624 (2009); 
9CFR113.101 [81] 
USDA SAM 
608 (2008) 
[98] 
Leptospira interrogans 
Serovar canicola bacterin 
(inactivated, non-adjuvanted)a,b
(swine, canine, cattle, equine 
Leptospirosis) 
USDA SAM 625 (2009); 
9CFR113.103 [48]; Ph. 
Eur. Monograph: 447 [49] 
USDA SAM 
609 (2008) 
[99] 
Leptospira interrogans 
Serovar grippotyphosa 
bacterina
(equine, swine, canine, sheep, 
goats, cattle Leptospirosis) 
USDA SAM 626 (2009); 
9CFR113.104 [82] 
USDA SAM 
617 (2008) 
[100] 
Leptospira interrogans 
Serovar icterohaemorrhagiae
bacterina
(swine, canine, cattle, equine 
Leptospirosis) 
USDA SAM 627 (2009); 
9CFR113.102 [83] 
USDA SAM 
610 (2008) 
[101] 
Leptospira interrogans 
Serovar hardjo bacterinb
(cattle, sheep, goats, equine 
Leptospirosis)
Antigen quantification – in
vitro ELISA 
9CFR113.105 [50]; Ph. 
Eur. Monograph 1939 
[51]; Hendriksen 2008 
[60] 
Immunization Challenge 
test in hamsterse
-
Clostridium chauvoei;
Bovine (Black Leg) 
In vitro ELISAb
(inactivated)
USDA Memo 800.104, 
2003 [102] 
Immunization followed 
by live spore challenge in 
guinea pigs 
SAM 220 
[103]; Ph. 
Eur. 
Monograph 
361 [104] 
Inactivated Viral Vaccines 
Bovine respiratory Viruses 
(BRV, BVD, PI3, BRSV)a
(Cattle respiratory disease) 
Antigen quantification – in
vitro ELISA 
USDA SAM 120 (1991) 
[84]; 9CFR113.216 (BRV) 
[105]; 9CFR113.115 
(BVD) [106] 
- -
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Vaccine Product 
(Disease) 
3Rs Alternative References for Alternative Methods
Traditional Test 
Procedure for which the 
Alternative Method is 
Applicable
References
for 
Traditional
Methods 
Feline Leukemia Virus 
(GP70)a
(Feline Leukemia) 
USDA SAM 321 (2007); 
9CFR113.8 [85];  
Immunization Challenge Shibley et al. 
1991 [107] 
Canine Coronavirusa
(Canine gastrointestinal 
disease)
USDA SAM 322 (2007) 
[86] 
Immunization Challenge 
test in puppies 
-
Newcastle Disease Virusb
(Chicken respiratory disease) 
Antigen quantificationc – in
vitro ELISA or Serology
Ph. Eur. Monograph: 870 
[108]; Hendriksen 2007 
[109]; Claassen et al. 2004 
[88] 
Immunization challenge 
in chickensf; Serology 
-
aAccepted by U.S. regulatory authorities.
bPublished in the European Pharmacopoeia.  
cApplicable after in-house (product-specific) validation. 
dDate is year of last SAM revision.  
eThe European Pharmacopoeia states endpoint is “signs” of disease and not lethality. 
fNot for routine batch release in Europe.
The availability of reference standards would enable vaccine manufacturers to develop their own standards for in-
house evaluations. Regulatory agencies such as the Animal and Plant Health Inspection Service (APHIS), the CVB, 
and the Biological Standardisation Programme (BSP) under the EDQM develop, produce, characterize, and 
distribute reference standards and other critical reagents. These references are provided to manufacturers to use in 
developing assays; comparing direct or indirect potency; or independently testing efficacy, identity, and purity. 
The challenges caused by the adjuvants that are present in many veterinary vaccines present the second key 
technical issue identified by workshop participants. These challenges must be addressed during the development of 
in vitro replacement alternatives. Typically, in vivo potency tests evaluate the protective or immune response to the 
complete vaccine, including antigenic material (e.g., adjuvants, excipients). However, many typically use adjuvants 
such as mineral oil and aluminum salts, which may interfere with in vitro quantification methods. Therefore, these 
adjuvants would need to be separated from the antigen component of the vaccine before in vitro potency testing. 
Because the adjuvant is a critical component for developing the appropriate protective response for inactivated 
vaccines, additional in vitro tests may be required to ensure their quality. Regardless, when antigen quantification 
methods are being developed, the effect of an adjuvant on the immunogenicity of the protective antigen will also 
need to be investigated [18, 88, 91]. In addition, the effect of the inactivant on in vitro potency methods must be 
investigated.  
A recent study showed that the method of inactivation (in this case, formaldehyde) on an oil-based adjuvanted 
inactivated Newcastle vaccine lowered the in vitro ELISA potency result but did not affect the in vivo potency result 
compared to the use of the inactivant B-propiolactone [110]. This study indicated that the in vitro potency results for 
commercial Newcastle vaccines inactivated with formaldehyde cannot be directly compared to those inactivated 
using B-propiolactone [110]. 
Validation of an in vitro potency assay begins when the assay is initially developed and involves establishing its 
relationship to efficacy in the target species. The protective antigen (protein) must be identified, purified, and shown 
to elicit protection in vaccinated animals. Antibodies to that protein should neutralize infectivity of the pathogen. 
Extensive validation continues through the assessment of the assay’s precision, accuracy, and ruggedness, toward 
the transition to implementation and use over time [111]. Workshop participants recommended the following high-
priority research, development, and validation activities.  
5.2.1. Rabies vaccines 
The current in vivo potency test for inactivated veterinary rabies vaccine comprises a multidilution vaccination–
challenge test in mice, traditionally termed the National Institute of Health (NIH) test. It is known to be highly 
variable with a high frequency of invalid results [112, 113, 114]. Recently implemented reduction and refinement 
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alternatives to this test include (1) the use of a single-dilution vaccination (reduction) [53] that results in a significant 
reduction in animal usage to approximately 60 mice per test and (2) the incorporation of earlier humane endpoints of 
paresis, paralysis, and convulsions (refinement) [52].  
In addition, several alternative serological methods have also been developed in which the rabies virus 
neutralizing antibodies are quantified from the serum of immunized animals. Two such serological methods include 
the rapid fluorescent focus inhibition test (RFFIT) [55, 115] and the fluorescent antibody virus neutralization test 
(FAVN) [54]. According to the European Pharmacopoeia, the RFFIT may be used after a correlation has been 
established with the mouse vaccination–challenge in vivo test. A recent study demonstrated good correlation 
between results from the RFFIT and the traditional in vivo challenge assay [55]. The RFFIT is also reproducible 
within and between laboratories, providing a potential alternative to the mouse vaccination–challenge assay [22, 56]. 
In fact, the European Pharmacopoeia recently published a revised draft monograph incorporating the RFFIT potency 
assay for inactivated rabies vaccines for veterinary use [53]. Considering these recent developments, workshop 
participants recommended a focused international workshop to discuss the barriers to international implementation 
of the RFFIT. 
Several types of antigen quantification tests are currently in development for inactivated rabies veterinary 
vaccines, including single radial diffusion tests, antibody-binding tests, and ELISA methods [57, 116, 117]. 
Although the ELISA assays are reproducible, inexpensive, and quantitative, they are currently product specific, and 
reagents are not universally available [116]. In addition, it has yet to be demonstrated that the antigen concentration 
in the vaccine can be correlated with an ability to stimulate a protective immune response [118]. Furthermore, 
guidance and/or recommendations from global regulatory agencies are necessary to resolve how any new alternative 
assay (i.e., serological or antigen quantification) can be validated against the current, highly variable in vivo assay 
[22, 116].  
There was broad recognition and general consensus among workshop participants that interaction between the 
human/veterinary regulatory agencies and vaccine manufacturers should be expanded. Such interaction would 
significantly increase, where appropriate, information exchange to keep all parties current on possible approaches 
that can be used to further the development and implementation of replacement alternatives for vaccine potency 
testing.  
The potency release test used for human rabies vaccines is similar to that used for veterinary products. All U.S.-
licensed rabies vaccines for human use define potency as the geometric mean of two valid NIH potency tests with 
humane endpoints defined [19]. In the EU, a similar vaccination–challenge procedure with humane endpoints is also 
described for human rabies vaccines [119]. The FDA has approved the replacement of several animal-based 
immunogenicity assays with ELISA-based potency assays for some vaccine products, but this does not include 
human rabies vaccines [19]. At issue is the fact that, although the neutralizing antigens are well defined, a clear 
correlation has not been demonstrated among the amount of antigen required to induce immune response in animals, 
the amount of antigen measured using alternative in vitro assays, and the immune response in human vaccines [19]. 
Consequently, serological assays may be required to serve as an intermediate step toward the successful 
development of an in vitro antigen quantification test.  
Although the development of a single potency test (i.e., serological, antigen quantification) for both human and 
veterinary rabies vaccines is the desired goal, it may be necessary to adapt the test for both product-specific and 
strain-specific vaccines [116]. Because of the clear synergies between human and veterinary rabies vaccines, 
workshop participants recommended as a priority that manufacturers and regulatory agencies worldwide collaborate 
on the development and validation of a refinement or replacement assay for all rabies vaccine products.
5.2.2. Leptospira spp. vaccines 
Briefly, the current in vivo Leptospira potency test consists of a vaccination–challenge procedure in hamsters, 
followed 14 days later with a lethal endpoint. The in vivo test is time consuming (more than five weeks) and exposes 
laboratory personnel to live, viable Leptospira, a zoonotic pathogen. The USDA recently developed a sandwich 
ELISA as an alternative in vitro test using rabbit polyclonal capture and a specific mouse monoclonal detecting 
antibody to measure the relative potency of specific bacterins compared to a qualified reference standard for several 
Leptospira interrogans serovars including pomona [81], canicola [37], grippotyphosa [82], and 
icterohaemorrhagiae [83]. Studies still to be completed include the testing of adjuvants and other vaccine 
components on assay interference [17]. The in vivo and in vitro assay methods are currently published by the USDA 
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in SAMs and European monographs (e.g., canine leptospiral antigen quantification method, Ph. Eur. Monograph 
447; Leptospira hardjo antigen quantification method, Ph. Eur. Monograph 1939) [49, 51, 60, 117]. 
In summary, the development and validation of an in vitro potency assay is product- and manufacturer-specific, 
and manufacturers must perform the necessary studies using specific regulatory memorandums as guidance 
throughout this process. As a secondary priority, workshop participants recommended the continued development 
and implementation of ELISA antigen quantification methods, including research into the effects of adjuvants and 
other vaccine excipients, and the harmonization of these tests among global regulatory authorities. 
5.2.3. Clostridium spp. vaccines 
The typical potency test for veterinary Clostridium spp. vaccines is an in vivo rabbit/mouse toxin-neutralization 
test currently used, for example, for Clostridium novyi [32, 33, 109] and Clostridium perfringens [37, 38,] (Table 1).
However, alternative methods for Clostridial toxoid potency testing have also been developed and published [34, 35, 
109]. For example, European regulatory authorities have a serological potency test for Clostridium perfringens [39] 
and Clostridium septicum [36] vaccines that has been accepted by European regulatory authorities, although 
product-specific validation is still required by each vaccine manufacturer [109]. For Clostridium chauvoei, an 
alternative approach using a validated ELISA method [102, 103] and an in vitro replacement test for Clostridium 
hemolyticum utilizing toxin-neutralizing antibodies with the characterized protective antigen, is described [22].
Potentially, all the Clostridium protective antigens could be evaluated by antigen quantification methods, such as 
quantitative ELISAs, after the protective antigen has been identified by gene cloning or after rights to the protective 
gene have been obtained from sources that have cloned the genes for the purpose of developing reference standards. 
Based upon the published literature and available regulatory methods, replacement of the toxin-neutralization test 
for specific Clostridium spp. vaccines is a realistic goal but will require the global recognition of reference vaccines 
and the identification of the target antigens for these vaccines. 
In addition to rabies vaccines, workshop participants agreed that a synergy among experts in human and 
veterinary tetanus vaccines could facilitate and expedite the development of a replacement potency test for both of 
these vaccine products. Currently, in the United States and the EU, the potency tests for human and veterinary 
vaccines consist of vaccination of guinea pigs and serological evaluation of antitetanus toxoid antibodies by an 
indirect ELISA [44] or a toxin-binding inhibition (ToBI) test [45, 47]. Efforts to develop a replacement test for 
either human or veterinary tetanus vaccines are impeded by the facts that toxoid vaccines are not well characterized, 
and potential analytical tests, including physiochemical and immunochemical tests, require much greater data 
generation, characterization, and validation for in-process and final product characterization [120].  
A proposed blueprint for the development of an in vitro replacement potency test for Clostridium tetani included 
(1) the validation of currently available physiochemical and immunochemical tests, (2) parallel testing of vaccines 
by in vitro and serological methods, and (3) regulatory acceptance and implementation [120, 121]. A focused, 
coordinated effort by human and veterinary tetanus vaccine experts to develop a replacement implementation plan 
was given a high priority by all workshop participants.
5.2.4. Foreign animal disease vaccines  
Vaccines for foreign animal diseases were identified as high priorities due to the biohazard imposed upon 
laboratory workers and the threat to livestock and wildlife. Foot and mouth disease is the most economically 
important viral livestock disease worldwide, infecting both domestic and wild cloven-footed animals including 
cattle, swine, sheep, goats, and deer [122, 123, 124]. Control of FMD has proven difficult because of the rapid 
replication of the virus, persistence of the virus in both infected and vaccinated animals, existence of multiple 
serotypes, and the lack of a globally available and effective vaccine supply [124, 125, 126].
Inactivated vaccines are commonly used but limited by the vaccines’ short shelf life, the short duration of 
immunity, the need to include many antigens to obtain broad immunity, and biosafety concerns with production of 
live virus [123, 124, 1237]. Improved vaccines currently in development include (1) recombinant protein and 
peptide vaccines, (2) DNA vaccines, (3) empty capsid vaccines, and (4) adenoviral or fowlpox-vectored vaccines 
[122, 123, 124, 127]. There is also growing need for a marker FMD vaccine that would differentiate infected from 
vaccinated animals (DIVA). The development of such a vaccine would be significant because vaccination can 
interfere with disease surveillance using serological testing, and may result in a country’s loss of FMD-free status 
and substantial economic loss [128].  
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As superior, functionally characterized vaccines are developed, greater opportunities to reduce, refine, or replace 
animal use in potency testing will undoubtedly arise. To date, the most successful vaccine strategy has been the 
development of a recombinant, replication-defective human adenovirus type 5 that expresses the FMD capsid 
sequence. Solid efficacy has been demonstrated in cattle and swine [124]. However, it is uncertain whether a single 
vaccine approach can successfully overcome all the shortcomings of the current inactivated vaccines. A combination 
of different vaccine strategies is likely to be required for effective disease control [124, 125].
Currently, the vast majority of FMD infections occur in Asia, Africa, and South America. FMD-free regions 
include North America, Europe, and Australia [124, 125]. Because of significant safety concerns associated with the 
production of large amounts of FMD virus, the United States prohibits live virus vaccine production on its mainland 
[124]. To achieve global disease control, vaccines with improved themostability and a longer duration of immunity 
are required, especially in those regions of the world without advanced infrastructures [125]. For the complete 
control and eradication of FMD, vaccination, surveillance, and an effective monitoring program are necessities 
[126].
5.2.5. Poultry vaccines 
Workshop participants recommended poultry vaccines as priorities for future research and development of in 
vitro assays because of the large number of target animals currently used in vaccination–challenge and vaccination–
serology testing procedures. In vitro potency testing of live viruses is typically performed in primary cell cultures 
using endpoints such as plaque formation and cytopathology. Examples of live virus poultry vaccines that use in 
vitro potency assessment include those for Marek’s disease [129] and infectious bursal disease [130]. Other 
examples of non-animal potency testing for poultry vaccines include a procedure for titrating Newcastle disease 
virus (NDV) vaccine, infectious bronchitis virus (IBV) vaccine, and a combination NDV-IBV vaccine that uses 
embryonated chicken eggs to determine the EID50 [76].  
As described earlier, an in vitro ELISA antigen quantification for inactivated NDV is validated and accepted for 
use in the EU [18, 87, 88. 89]. Additional antigen quantification assays have been developed for infectious bursal 
disease virus and IBV vaccines; however inadequate funding has prevented further validation [18, 87, 131]. 
Although the technology is now available, sufficient resources and efforts must still be adequately applied to 
validate these replacement potency assays and gain regulatory approval. Finally, as new and better characterized 
poultry vaccines are developed through the use of viral-vectored systems, purified recombinant proteins, or DNA 
vaccines, alternative in vitro approaches to potency testing should become available [128].  
5.2.6. Fish vaccines 
Fish vaccine potency tests were highlighted at the workshop because of the large number of animals used, 
including unvaccinated controls, in vaccination–challenge procedures [14]. The majority of fish vaccine potency 
release tests consist of host animal vaccination–challenge methods. Little progress has been achieved in reducing, 
refining and replacing the use of animals (fish) for this process [132]. Fish inactivated bacterial vaccines have been 
successfully used in aquaculture, but only recently has the industry developed effective viral vaccines. The number 
of available fish vaccines increased significantly in the 1990s [133]. Increasingly, adjuvants and immunostimulants 
are being used to enhance vaccine potency in fish, thereby further complicating the ability to develop refinement or 
replacement potency testing procedures [134].
For many fish vaccines, the correlation of serological response and protection is not well established either, 
impeding the development of serological potency tests [132]. However, some protective antigens have been 
identified for inactivated bacterial vaccines, such as those protecting from Vibrio salmonicida and Vibrio
anguillarum diseases. This suggests that serology or antigen quantification methods could be developed for selected 
vaccine products [132]. Finally, research and development efforts are expected to expand as additional fish vaccines 
enter the market and more animal health companies develop vaccines for aquaculture use.
Each of the priority vaccines described above requires a significant investment of time and resources because of 
(1) the complexities associated with moving from an in vivo test method to one that does not require animals and (2) 
the costs associated with the significant research, development, and validation of in vitro vaccine potency test 
methods [18, 22]. Therefore, early and frequent interactions with regulators are strongly encouraged throughout this 
process to maximize the likelihood of a final product that will be accepted by regulatory authorities and to avoid any 
unnecessary delays.  
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6. Achieving broader acceptance and use of currently available non-animal replacement methods for 
veterinary vaccine potency testing 
Workshop participants agreed that the primary impediment to broader acceptance and use of available non-
animal replacement methods is the associated cost and time required for each vaccine manufacturer to conduct a 
product-specific validation of the in vitro potency assay for each specific vaccine. In addition, the lack of 
international harmonization on alternative potency methods often means that the veterinary vaccine manufacturer 
must perform multiple potency release tests for the same vaccine depending on its point of manufacture and use. As 
a starting point, workshop participants recommended that regulatory agencies harmonize the general principles for 
the validation of alternative potency tests. In the United States, the CVB has issued general guidelines on the 
validation of in vitro potency assays [111] and relative potency assays and reference preparations based on ELISA 
antigen quantification [135].  
International organizations also play an important role in this harmonization process. The International 
Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products 
(VICH) is a trilateral program of collaboration among the regulatory authorities and animal health industries of the 
European Union, Japan, and the United States. The VICH aims to harmonize technical requirements for the 
registration of veterinary medicinal products by establishing and implementing specific guidelines after extensive 
input and review from national regulatory authorities. The VICH was established under the auspices of the World 
Organization of Animal Health (OIE), which participates as an associate member in the VICH process by supporting 
and disseminating the outcomes at a worldwide level (http://www.vichsec.org). As VICH guidelines are developed 
and reviewed by members of the international animal health community, there is increased acceptance of the 
regulatory principles that should facilitate faster and more uniform implementation. Examples of VICH guidelines 
that have been adopted by APHIS include VICH GL 41: Examination of Live Veterinary Vaccines in Target 
Animals for Absence of Reversion to Virulence (VICH 2007 (adopted by the U.S. in 2008) and GL 44: Target 
Animal Safety for Veterinary Live and Inactivated Vaccines (2008) (adopted in the U.S. in 2010). In addition, a 
draft guideline is in development by VICH to consider a waiver for the Target Animal Batch Safety Test [26].  
In addition to harmonizing general principles, there is a need to harmonize the testing procedures for individual 
vaccine antigens, including development of the necessary reagents. For example, reference standards such as 
specific antibodies, viruses, bacteria, and antigens can be accessed from the CVB by U.S. entities to aid in the 
development of in vitro potency test assay development. Broad international availability of reference standards, 
supported by the national and regional regulatory authorities, would greatly help to convert animal-based tests to 
non-animal assays. Additionally, universal reference standards could be monitored and maintained by organizations 
such as the OIE, USDA, World Health Organization (WHO), or EDQM.  
The availability of reference standards is a key factor in the ability of vaccine manufacturers to switch to an in 
vitro replacement assay. For example, in an ELISA, the reference must be analyzed in conjunction with the sample 
so that a direct comparison of test vaccine to a known reference can be used to determine a relative potency. 
Relative potency is defined by the CVB as the potency of a product as determined by comparison with an approved 
reference [135]. For in vitro antigen potency assays, the unknown is typically compared with a working reference 
that was generated from the master reference. The master reference potency must have been previously correlated, 
directly or indirectly, to host animal immunogenicity.  
As the master reference is correlated to host immunogenicity, its relative stability must be monitored over time to 
ensure that the reference remains stable during storage. Currently, in the United States a frozen master reference is 
allowed a maximum dating of five years or, if stored under refrigeration, a maximum dating of two years [135]. 
After the dating period, each reference must be requalified in the host animal immunogenicity test. To avoid the use 
of additional animals for requalification, workshop participants recommended that requalification be conducted in 
any currently acceptable potency test. 
Development of new requalification tests is the responsibility of the vaccine manufacturer. This requires 
significant resources, especially in the development stage. Vaccine manufacturers cannot afford to dedicate these 
resources to products that are older and less profitable. Therefore, prioritization of veterinary vaccines for 
replacement testing and the potential availability of reference standards can significantly accelerate the animal test 
replacement process. 
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Workshop participants recommended that stability monitoring for both products and reference standards be 
considered early in the development process. They recommended that regulatory authorities work with industry 
stakeholders to set expectations for the stability monitoring program [17]. The stability monitoring of references 
typically requires that multiple previously validated tests be conducted on a 3-, 6-, or 12-month schedule (Brown 
2010, personal communication). As test methods change so might the stability monitoring methods and even the 
reference standard itself. Consequently, regulatory agencies may require flexibility to work with the vaccine 
manufacturers in bridging reference standards and methodologies as industry moves toward in vitro replacement 
assays.
Regulatory guidance will also be required on the development and application of new technologies to the 
development of veterinary vaccines such as genetically engineered (rDNA) products, including inactivated/subunit, 
live (or inactivated) gene-deleted, or live vector (gene insertion) products [17].  
Clearly, vaccine manufacturers must decide which products to prioritize for specific non-animal replacement 
potency testing. Typically, considering the output of industry resources, this decision is based upon product revenue 
and profitability. To aid in this process and to expedite replacement testing, sufficient resources are essential to 
develop and maintain reference standards specifically for industry use. In addition, broad accessibility of general 
procedural guidelines (as well as specific testing procedures) for individual antigens would further facilitate the 
international harmonization of replacement assay development and use. 
7. Other issues to be addressed to facilitate the replacement of animals in veterinary vaccine potency testing
A key issue that should be addressed is the available funding for research and development of alternative 
methods. This research and development should be funded not just by industry stakeholders but also by government 
granting agencies, industry associations, and animal welfare advocacy groups. For example, the U.S. National 
Institutes of Health may offer funding opportunities for veterinary vaccines for those animal diseases associated 
with human health, such as rabies. Furthermore, academic research into test method alternatives should be 
promoted, and manufacturers should be encouraged, where appropriate, to present and/or publish their research 
findings regarding their alternative test methods.  
Workshop participants also encouraged the increased availability of regulatory guidance documents in the public 
domain.  
As indicated in Section 5, the inclusion of adjuvants in veterinary vaccines complicates the development of 
alternative methods because of their reported interference with antigen quantification assays. Consequently, priority 
should be given to developing replacement potency tests for vaccines that do not contain adjuvants. Where 
adjuvants are required, priority should be given to those adjuvants for which methods already exist to separate the 
adjuvant from the antigen. Newly developed adjuvants improve the immune response but may also be more difficult 
to separate from the antigen. In such instances, regulatory agencies may consider allowing manufacturers to measure 
potency on the bulk material, before the addition of adjuvant, or allowing antigen testing on the bulk material with 
an additional characterization/quantitative test on the final product. There is a clear need for further research on 
simpler adjuvants (and/or the methods to extract then) that may exert an effect on the animal’s immune system but 
that do not directly interact with the antigen.  
Detailed protocols for available replacement alternatives that have been reviewed and endorsed by scientific 
groups should be readily available in the public domain to facilitate scientific exchange and consideration. For 
example, detailed protocols and supporting data for validated methods, such as those that appear or are referenced in 
the European Pharmacopoeia monographs, should be freely available to manufacturers and the scientific community 
to facilitate the implementation of alternative methods. 
Further incentives for industry stakeholders to develop, validate, and implement alternative methods need to be 
clearly conveyed and implemented by regulatory agencies. Workshop participants identified several examples of 
incentives that may be considered attractive to relevant vaccine manufacturers, including an expedited regulatory 
review time, waiving the variation fee (if applicable), and the opportunity to utilize intermittent in vivo/in vitro
parallel data to expedite validation of new in vitro methods.  
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8. Discussion
This was the first international workshop in the United States that focused on the reduction, refinement, and 
replacement of animal use for safety and potency release testing of both human and veterinary vaccines. A key 
accomplishment of the workshop was bringing together experts from industry, academia, and government in the 
areas of safety and potency testing for both human and animal vaccines. There was broad recognition among the 
vaccine manufacturers and regulatory authorities and a general consensus among the participants that international 
workshops vastly improve information exchange not only between global regions but also between regulatory 
authorities (e.g., the USDA and the FDA) in the same country. This interaction may accelerate development of 
alternative methods once priorities are firmly established.  
The presentations and subsequent breakout group sessions allowed participants to clarify the current status of in 
vitro replacement testing procedures and establish the key criteria to identify those vaccines for prioritization. A 
focus on inactivated vaccines for rabies, Leptospira spp., and Clostridium spp. diseases was generated from this 
debate. An important outcome of this workshop was the recommendation for a similar international workshop to 
specifically discuss the development, validation, and implementation of alternative reduction, refinement, and 
replacement potency testing assays for rabies vaccines for both human and veterinary use. This workshop is 
currently scheduled for October 11–13, 2011 in Ames, Iowa. 
The workshop reflected a growing awareness of the need for alternative tests for both poultry and fish vaccines, 
in which the vaccines are typically tested in large numbers of target animals. Because the number of fish vaccines 
has grown significantly in the last 20 years, much more research and greater focus is needed to identify protective 
antigens for replacement testing. Finally, workshop participants recognized the uniqueness of veterinary vaccines 
and the need to focus on more-modern, stronger revenue-generating vaccines that can support the cost of new test 
method development. 
This workshop also brought attention to (1) the development and use of more-complex adjuvants and (2) the use 
of multiple adjuvants to generate solid and sustained immunity with poorer immunogens (vaccines) and to lower 
vaccine antigen levels. The use of more-complex or multiple adjuvants further complicates potency replacement 
efforts and therefore highlights the need for much more extensive research into simpler adjuvants and/or methods to 
extract them from the protective antigen.  
Workshop participants were encouraged by the significant number (estimated to be between 50% and 70%) of 
veterinary vaccines, especially the modified live viral and bacterial vaccines that now use in vitro potency tests. 
Clearly, better estimates of the number of veterinary vaccine serials released using replacement methods would be 
beneficial and would also focus the discussion on those vaccines for which replacement potency testing is not yet 
available or in use.
Accessing the information on the current state of the art of veterinary vaccine potency tests is challenging 
because some procedures or general guidelines are not universally available. This results in an unnecessary 
hindrance to the implementation of the 3Rs for vaccine product release.
The growing role of international organizations such as the VICH and the OIE is apparent. Workshop participants 
agreed that the harmonization of guidelines and reference standards for broad use by the vaccine community would 
likely increase the interaction between those organizations and the national regulatory groups. In addition, workshop 
participants clearly expressed the need for additional funding for these regulatory groups to allow greater 
availability of some of these key reagents (e.g., reference standards) to vaccine manufacturers. Although the vaccine 
companies must develop and validate product-specific assays, the reference standards would provide the basis for 
this further development and validation.  
This workshop set the stage for a series of specific workshops on the identified priority vaccines. Based upon the 
general scientific literature and the presentations at the workshop, there is broad international consensus to reduce, 
refine, and replace the use of animals for both human and veterinary vaccine potency testing. Implementation of the 
workshop recommendations discussed in this report is expected to advance alternative methods for veterinary 
vaccine potency testing that will benefit animal welfare while ensuring continued protection of human and animal 
health.  
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9. Conclusions 
This veterinary vaccine session summarized the current status of in vitro potency testing for veterinary vaccines 
and identified the critical issues to further advance and implement in vitro replacement assays for currently used in 
vivo challenge or toxin-neutralization testing. To focus these efforts, criteria were established for vaccines that 
should have the highest priority for development of replacement testing methods. Based upon these criteria, the 
highest-priority vaccines were identified as those for rabies, Leptospira spp., Clostridium spp., erysipelas, foreign 
animal diseases (e.g., FMD), poultry diseases, and fish diseases. Workshop participants also prioritized the research, 
development, and validation activities necessary to expedite veterinary vaccine potency testing with fewer animals.  
Workshop participants recognized that there are special considerations with veterinary vaccines due to the 
complexity of antigenic material and the inclusion of complex adjuvants. They acknowledged that, in many cases, 
reduction/refinement testing may precede the introduction of in vitro replacement assays. This, combined with the 
number of veterinary vaccines and their value to the veterinary industry, suggests that the priorities identified are 
correct and have the highest chance of successful implementation. 
There was consensus among workshop participants on the need for more universally available reagents and 
harmonized approaches. The successful implementation of these activities will require additional resources at both 
national and international levels. Finally, workshop participants agreed that the continued interaction of the global 
vaccine community (i.e., manufacturers, regulatory agencies, animal health organizations), both human and 
veterinary, could expedite the unified goal of the replacement of animals for veterinary vaccine potency testing. 
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